Microplastics found in carotid artery plaque are associated with a 4.5x higher risk of heart attack, stroke, or death, but cardiologists have no way to test for or treat plastic accumulation in arterial walls

A landmark 2024 study published in the New England Journal of Medicine analyzed carotid artery plaque removed during endarterectomy surgery from 304 patients. Polyethylene was detected in the arterial plaque of 58.4% of patients, and 12.1% also had measurable polyvinyl chloride. The patients whose plaque contained microplastics and nanoplastics had a hazard ratio of 4.53 for the composite endpoint of heart attack, stroke, or death from any cause over 34 months of follow-up. That is a 4.5x higher risk — a stronger association than many established cardiovascular risk factors. This finding transforms microplastic exposure from an environmental concern into an immediate clinical cardiology problem. Cardiovascular disease is already the leading cause of death globally, killing roughly 18 million people per year. If microplastic accumulation in arterial plaque is even partially causal — through inflammatory mechanisms, oxidative stress, or disruption of endothelial function — then a significant fraction of cardiovascular events may be driven by a risk factor that no cardiologist currently screens for, no drug targets, and no lifestyle intervention can reverse once the particles are embedded. Patients undergoing routine cardiac risk assessment get their cholesterol checked, their blood pressure measured, and their family history reviewed, but nobody measures the plastic content of their arteries. The problem persists because the detection method used in the NEJM study — pyrolysis-gas chromatography-mass spectrometry — requires excised tissue samples and specialized laboratory equipment. There is no blood test, imaging modality, or noninvasive screening tool that can quantify microplastic burden in arterial walls. Even if such a test existed, there is no therapeutic intervention to remove embedded microplastics from plaque. The entire clinical pipeline — from diagnosis to treatment — is missing. Meanwhile, the study establishes an association but cannot prove causation from a single observational cohort, so funding agencies and guideline committees lack the evidence base to act, creating a catch-22 where the necessary interventional trials cannot be designed until the diagnostic tools exist.